Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Jul-Aug;26(4):431-9.
doi: 10.1007/s00246-004-0814-2. Epub 2004 Sep 15.

Use of covered stents in the management of coarctation of the aorta

Affiliations
Comparative Study

Use of covered stents in the management of coarctation of the aorta

C A C Pedra et al. Pediatr Cardiol. 2005 Jul-Aug.

Abstract

We report our experience with the use of covered stents for the management of coarctation of the aorta. From December 2001 to March 2004, nine patients (seven males; median age, 31 years; mean weight, 65 +/- 15 kg) underwent implantation. Indications included critical or atretic native coarctation (n = 4), patients >50 years of age (n = 2), associated patent ductus arteriosus (n = 1) or adjacent aneurysm (n = 1), and the presence of a circumferential fracture within a previously implanted stent (n = 1). The covered balloon-expandable Cheatham-Platinum stent and the self-expandable stent graft Braile were employed. Adequate implantation was observed in all patients. Gradients were reduced from 54 +/- 14 to 3 +/- 8 mmHg and the coarctation site increased from 2.4 +/- 2.9 to 15.9 +/- 4.3 mm. The patent ductus arteriosus was immediately closed and the aneurysm excluded. Two patients >35 years with aneurysmal ascending aorta and metallic aortic prosthesis had aneurysm formation at follow-up, with one undergoing aneurysm exclusion using a Braile stent. Although covered stents are useful in the management of selected patients with coarctation, aneurysm formation may still occur in patients with markers of aortic wall weakness. Refinements in the deployment technique and/or the stent design are needed to eliminate this risk.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ann Thorac Surg. 2002 Apr;73(4):1143-8 - PubMed
    1. J Am Coll Cardiol. 1995 Mar 1;25(3):730-4 - PubMed
    1. Catheter Cardiovasc Interv. 1999 May;47(1):39-40 - PubMed
    1. J Am Coll Cardiol. 1996 Dec;28(7):1810-7 - PubMed
    1. Catheter Cardiovasc Interv. 2002 Jun;56(2):262-6 - PubMed

Publication types

Substances

LinkOut - more resources